NCT05905458View on ClinicalTrials.gov

A Phase II Clinical Study of the Efficacy and Safety of HRS9950 Tablets in Chronic Hepatitis B Patients Who Are Virologically Suppressed on Nucleoside or Nucleotide Analogues (NAs)

PHASE2CompletedINTERVENTIONAL
Enrollment

54

Participants

Timeline

Start Date

July 28, 2023

Primary Completion Date

November 22, 2024

Study Completion Date

November 22, 2024

Conditions
Chronic Hepatitis B
Interventions
DRUG

HRS9950 tablets

HRS9950 tablets, oral, once a week, low dose

DRUG

HRS9950 tablets

HRS9950 tablets, oral, once a week, high dose

DRUG

HRS9950 placebo tablets

HRS9950 placebo tablets, oral, once a week.

Trial Locations (1)

510515

Nanfang Hospital, Guangzhou

All Listed Sponsors
lead

Chengdu Suncadia Medicine Co., Ltd.

INDUSTRY